On April 29, the FDA approved the biologics license for a new product, Ixinity, a recombinant coagulation factor IX drug, by Cangene Corporation. A spokesperson for the parent company Emergent BioSolutions, Inc. said the product should be available within 60 days. As such, it should be released by the end of the month.
This month is Men’s Health Month. It’s supported by a congressional health education program, and celebrated across the country with a number of health fairs, screenings, and activities designed for health education and outreach.
The comprehensive health management service at Martin Health System of Stuart, Florida now includes pharmacist-led care in doctors’ offices. The new approach targets patients suffering from multiple chronic conditions including: diabetes, high blood pressure, high cholesterol, chronic obstructive pulmonary disease (COPD), asthma, and heart failure.
Skin cancer is the most common form of cancer in America. Ultraviolet (UV) radiation from the sun is the main cause, though UV radiation from sunlamps and tanning beds can also lead to skin cancer. Melanoma is the most dangerous kind of skin cancer. When skin cancer is found and treated in its early stages, […]
In late March, Sanofi Pasteur Inc. and the FDA announced a newly licensed vaccination safe for use in children ages four to six. This combination vaccine will complete the diphtheria, tetanus, and pertussis (DTaP) vaccination series, as well as provide an inactivated poliovirus vaccination series.
Since April is Minority Health Month, the Centers for Disease Control and Prevention (CDC) and the Department of Health and Human Services (DHHS) are you coming together to promote “Prevention is Power: Taking Action for Health Equity!”
In early March, Hospira announced the recall of lot 42-120-JT of the magnesium sulfate in 5% dextrose injection, because the barcode on the bag may actually be the machine readable barcode for 1000 mL bags of heparin sodium two units per milliliter. According to the FDA, the company voluntarily issued the recall.
A mid-January directive to state survey agencies provides new details about Medicare’s expectations for pharmacy activities and compounding practices at critical access hospitals.
